Biotech M&A is picking back up - here are the latest deals

While M&A was plentiful in 2018 and 2019, and even held up during a year gripped by the onset of the pandemic, 2021 and 2022 were much quieter. Analysts and other industry watchers have been forecasting a rebound for some time, but that has yet to materialize. Some have argued that’s due to both new challenges and, perhaps, changing attitudes of would-be buyers.